WE‐C‐BRB‐06: Clinical Impact of Uncertainties in the Mean Excitation Energy of Human Tissues during Proton Therapy

A. Besemer, H. Paganetti, B. Bednarz

Research output: Contribution to journalArticle

Abstract

Purpose: Uncertainties in the estimated mean excitation energies (I‐value) needed forcalculating proton stopping power can be in the order of 10–15%, which introduces afundamental limitation in the accuracy of proton range determination. Previous efforts havequantified shifts in proton depth dose distributions due to I‐value uncertainties in homogenoustissue phantoms. This study is the first to quantify the clinical impact of I‐value uncertainties onproton dose distributions within patient geometries. Methods: A previously developed Geant4 based Monte Carlo code was used to simulate aproton treatment plan for prostate cancer with varying tissue I‐values. A total of five cases weresimulated using nominal I‐values as well as I‐values modified by ±5% and ±10% of the nominalvalues. Dose volume histograms were generated for the GTV, CTV, PTV and relevant organs‐at‐risk (OARs). Results: Modification of tissue I‐values impacted both the proton range and SOBP width. D90range shifts up to 4 mm from the nominal range were recorded whereas D80 range shiftsreached up to 2 mm. For an increase in I‐value of 10% of the nominal value, the increase inrange and SOBP width resulted in a 1.4% decrease in the CTV mean dose. Inversely, decreasing the I‐value by 10% increased the CTV mean dose by 0.8%. The difference in themean dose to the OARs was relatively small except for the rectum that differedby up to 5%. Conclusions: This study demonstrated that the impact of I‐value uncertainties on patient dosedistributions. Clearly, sub‐millimeter precision in proton therapy would necessitate reduction in I‐value uncertainties to ensure an efficacious clinical outcome.

Original languageEnglish (US)
Number of pages1
JournalMedical physics
Volume39
Issue number6
DOIs
StatePublished - Jun 2012

Fingerprint

Proton Therapy
Uncertainty
Protons
Rectum
Prostatic Neoplasms

ASJC Scopus subject areas

  • Biophysics
  • Radiology Nuclear Medicine and imaging

Cite this

WE‐C‐BRB‐06 : Clinical Impact of Uncertainties in the Mean Excitation Energy of Human Tissues during Proton Therapy. / Besemer, A.; Paganetti, H.; Bednarz, B.

In: Medical physics, Vol. 39, No. 6, 06.2012.

Research output: Contribution to journalArticle

@article{0ef50338167344ca973f882c577c6084,
title = "WE‐C‐BRB‐06: Clinical Impact of Uncertainties in the Mean Excitation Energy of Human Tissues during Proton Therapy",
abstract = "Purpose: Uncertainties in the estimated mean excitation energies (I‐value) needed forcalculating proton stopping power can be in the order of 10–15{\%}, which introduces afundamental limitation in the accuracy of proton range determination. Previous efforts havequantified shifts in proton depth dose distributions due to I‐value uncertainties in homogenoustissue phantoms. This study is the first to quantify the clinical impact of I‐value uncertainties onproton dose distributions within patient geometries. Methods: A previously developed Geant4 based Monte Carlo code was used to simulate aproton treatment plan for prostate cancer with varying tissue I‐values. A total of five cases weresimulated using nominal I‐values as well as I‐values modified by ±5{\%} and ±10{\%} of the nominalvalues. Dose volume histograms were generated for the GTV, CTV, PTV and relevant organs‐at‐risk (OARs). Results: Modification of tissue I‐values impacted both the proton range and SOBP width. D90range shifts up to 4 mm from the nominal range were recorded whereas D80 range shiftsreached up to 2 mm. For an increase in I‐value of 10{\%} of the nominal value, the increase inrange and SOBP width resulted in a 1.4{\%} decrease in the CTV mean dose. Inversely, decreasing the I‐value by 10{\%} increased the CTV mean dose by 0.8{\%}. The difference in themean dose to the OARs was relatively small except for the rectum that differedby up to 5{\%}. Conclusions: This study demonstrated that the impact of I‐value uncertainties on patient dosedistributions. Clearly, sub‐millimeter precision in proton therapy would necessitate reduction in I‐value uncertainties to ensure an efficacious clinical outcome.",
author = "A. Besemer and H. Paganetti and B. Bednarz",
year = "2012",
month = "6",
doi = "10.1118/1.4736099",
language = "English (US)",
volume = "39",
journal = "Medical Physics",
issn = "0094-2405",
publisher = "AAPM - American Association of Physicists in Medicine",
number = "6",

}

TY - JOUR

T1 - WE‐C‐BRB‐06

T2 - Clinical Impact of Uncertainties in the Mean Excitation Energy of Human Tissues during Proton Therapy

AU - Besemer, A.

AU - Paganetti, H.

AU - Bednarz, B.

PY - 2012/6

Y1 - 2012/6

N2 - Purpose: Uncertainties in the estimated mean excitation energies (I‐value) needed forcalculating proton stopping power can be in the order of 10–15%, which introduces afundamental limitation in the accuracy of proton range determination. Previous efforts havequantified shifts in proton depth dose distributions due to I‐value uncertainties in homogenoustissue phantoms. This study is the first to quantify the clinical impact of I‐value uncertainties onproton dose distributions within patient geometries. Methods: A previously developed Geant4 based Monte Carlo code was used to simulate aproton treatment plan for prostate cancer with varying tissue I‐values. A total of five cases weresimulated using nominal I‐values as well as I‐values modified by ±5% and ±10% of the nominalvalues. Dose volume histograms were generated for the GTV, CTV, PTV and relevant organs‐at‐risk (OARs). Results: Modification of tissue I‐values impacted both the proton range and SOBP width. D90range shifts up to 4 mm from the nominal range were recorded whereas D80 range shiftsreached up to 2 mm. For an increase in I‐value of 10% of the nominal value, the increase inrange and SOBP width resulted in a 1.4% decrease in the CTV mean dose. Inversely, decreasing the I‐value by 10% increased the CTV mean dose by 0.8%. The difference in themean dose to the OARs was relatively small except for the rectum that differedby up to 5%. Conclusions: This study demonstrated that the impact of I‐value uncertainties on patient dosedistributions. Clearly, sub‐millimeter precision in proton therapy would necessitate reduction in I‐value uncertainties to ensure an efficacious clinical outcome.

AB - Purpose: Uncertainties in the estimated mean excitation energies (I‐value) needed forcalculating proton stopping power can be in the order of 10–15%, which introduces afundamental limitation in the accuracy of proton range determination. Previous efforts havequantified shifts in proton depth dose distributions due to I‐value uncertainties in homogenoustissue phantoms. This study is the first to quantify the clinical impact of I‐value uncertainties onproton dose distributions within patient geometries. Methods: A previously developed Geant4 based Monte Carlo code was used to simulate aproton treatment plan for prostate cancer with varying tissue I‐values. A total of five cases weresimulated using nominal I‐values as well as I‐values modified by ±5% and ±10% of the nominalvalues. Dose volume histograms were generated for the GTV, CTV, PTV and relevant organs‐at‐risk (OARs). Results: Modification of tissue I‐values impacted both the proton range and SOBP width. D90range shifts up to 4 mm from the nominal range were recorded whereas D80 range shiftsreached up to 2 mm. For an increase in I‐value of 10% of the nominal value, the increase inrange and SOBP width resulted in a 1.4% decrease in the CTV mean dose. Inversely, decreasing the I‐value by 10% increased the CTV mean dose by 0.8%. The difference in themean dose to the OARs was relatively small except for the rectum that differedby up to 5%. Conclusions: This study demonstrated that the impact of I‐value uncertainties on patient dosedistributions. Clearly, sub‐millimeter precision in proton therapy would necessitate reduction in I‐value uncertainties to ensure an efficacious clinical outcome.

UR - http://www.scopus.com/inward/record.url?scp=85024797471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024797471&partnerID=8YFLogxK

U2 - 10.1118/1.4736099

DO - 10.1118/1.4736099

M3 - Article

AN - SCOPUS:85024797471

VL - 39

JO - Medical Physics

JF - Medical Physics

SN - 0094-2405

IS - 6

ER -